Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

Олокизумаб

Многоцентровое открытое исследование III фазы для оценки эффективности и безопасности олокизумаба у пациентов со среднетяжелым и тяжелым активным ревматоидным артритом (CREDO 4)

Разрешение№ 670 от 20.09.2016
Номер протоколаCL04041024
ФазаФаза III
Участников по плану452
Сроки01.10.2016 — 30.06.2022
РазработчикАО «Р-Фарм»
Страна разработчикаРоссия
Начало: 1 октября 2016Окончание: 30 июня 2022
Плановый срок исследования истёк
Статус рассчитан по плановой дате окончания. В реестре указано: «Проводится».

Постоянная ссылка: https://clinomir.ru/trials/permit/ru/670/2016-09-20/

Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 452 чел. в стране «Россия».
  • Центров в реестре: 41 в 21 городах. Список — ниже на странице.
  • Плановая дата окончания (06.2022) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 19

Критерии включения

  • Subjects may be enrolled in the study only if they meet all of the following criteria:
  • Subject must be willing and able to sign informed consent
  • Subject must have completed the 24-week double-blind Treatment Period in 1 of the 3 core studies (CL04041022, CL04041023, or CL04041025).
  • Subject must have maintained their stable dose (and route) of MTX 15 to 25 mg/week (or ≥ 10 mg/week if there is documented intolerance to higher doses) during the core study and plan to maintain the same dose and route of administration for ≥ 12 additional weeks
  • Subjects must be willing to take folic acid or equivalent throughout the study.

Критерии невключения

  • Subject with any medically important condition in the core study (e.g., clinically significant laboratory values, frequent Adverse events (AEs) or serious adverse events (SAEs), infection SAEs, and/or other concurrent severe and/or uncontrolled medical condition) which would make this subject unsuitable for inclusion in the open-label extension (OLE) study in the Investigator's judgement.
  • Subject has evidence of active tuberculosis (TB)
  • Subject with a positive or repeated indeterminate interferon-gamma release assay (IGRA) result at Week 22 of the core study
  • \- Subjects may be enrolled in the OLE study if they fulfill all 3 of the following criteria prior to the first dose of study treatment:
  • Active TB is ruled out by a certified TB specialist or pulmonologist who is familiar with diagnosing and treating TB (as acceptable per local practice);
  • The subject starts prophylaxis for latent TB infection (LTBI) according to country-specific/Centers for Disease Control and Prevention (CDC) guidelines (treatment with isoniazid for 6 months is not an appropriate prophylactic regime for this study and it should not be used); and
  • The subject is willing to complete the entire course of recommended LTBI therapy.
  • Subject has planned surgery during the first 12 weeks of the OLE study
  • Female subjects who are pregnant or who are planning to become pregnant during the study or within 6 months of the last dose of study drug
  • Female subjects of childbearing potential (unless permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status \[e.g., correlative age\] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol <20 pg/mL) who are not willing to use a highly effective method of contraception during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment.
  • Highly effective contraception is defined as:
  • Female sterilization surgery: hysterectomy, surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks prior to the first dose of study treatment in the core study
  • In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by documented follow-up hormone level assessment
  • Total abstinence if it is the preferred and constant lifestyle of the subject. Thus, periodic abstinence such as ovulation, symptothermal, postovulation, calendar methods, and withdrawal are not acceptable methods of contraception.
  • Male sterilization surgery: at least 6 months prior to the first dose of study treatment in the core study (with the appropriate postvasectomy documentation of the absence of sperm in the ejaculate). For female subjects, the vasectomized male should be the only partner.
  • Placement of established intrauterine device (IUD): IUD copper or IUD with progesterone
  • Barrier method (condom and intravaginal spermicide, cervical caps with spermicide, or diaphragm with spermicide) in combination with the following: established oral, injected, or implanted hormone methods of contraception or contraceptive patch.
  • Subject is unwilling or unable to follow the procedures outlined in the protocol.
  • Other medical or psychiatric conditions, or laboratory abnormalities that may increase the potential risk associated with study participation and administration of the study treatment, or that may affect study results interpretation and, as per Investigator's judgement, make the subject ineligible.

Источник: ClinicalTrials.gov, NCT03120949 · запись обновлена в реестре 12 октября 2023.

Дизайн и результаты

ДизайнРандомизированное, открытое (без ослепления), параллельные группы; цель — лечение
Включено участников (факт, все страны)2 106
Что измеряют — первичные конечные точки (7), вторичных — 14
  • Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) — up to Week 126
  • Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) — up to Week 126
  • Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI) — up to Week 126
  • Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment — up to Week 126
  • Incidence Rate of Treatment Emergent AEs Per Patient-years of Exposure — up to Week 126
  • Incidence Rate of Treatment Emergent SAEs Per Patient-years of Exposure — up to Week 126
  • Incidence Rate of Treatment Emergent AESIs (Safety Population) — up to Week 126

Цель исследования

The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately to severely active rheumatoid arthritis (RA) who previously had completed 24 weeks of double-blind treatment in Study CREDO 1, 2 or 3 (core studies). The long-term efficacy, immunogenicity, the physical function and quality of life of subjects received long-term treatment with OKZ were assessed as well.

Области и заболевания

Где проходит

41 центр в 21 городе
Москва

Откуда эта информация

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.